

# Stephanie Kreis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8074304/publications.pdf>

Version: 2024-02-01

23  
papers

950  
citations

567144

15  
h-index

642610

23  
g-index

23  
all docs

23  
docs citations

23  
times ranked

2183  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E9271-E9279.	3.3	181
2	Many ways to resistance: How melanoma cells evade targeted therapies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 313-322.	3.3	166
3	ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. <i>Molecular Cancer</i> , 2017, 16, 102.	7.9	108
4	Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer?. <i>Oncotarget</i> , 2015, 6, 12110-12127.	0.8	77
5	NRAS mutant melanoma: Towards better therapies. <i>Cancer Treatment Reviews</i> , 2021, 99, 102238.	3.4	56
6	A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells. <i>Molecular Cancer</i> , 2018, 17, 145.	7.9	54
7	Transferring intercellular signals and traits between cancer cells: extracellular vesicles as "homing pigeons". <i>Cell Communication and Signaling</i> , 2016, 14, 13.	2.7	32
8	Hypoxia-Induced Adaptations of miRNomes and Proteomes in Melanoma Cells and Their Secreted Extracellular Vesicles. <i>Cancers</i> , 2020, 12, 692.	1.7	32
9	Modulation of the IL-6-Signaling Pathway in Liver Cells by miRNAs Targeting gp130, JAK1, and/or STAT3. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 16, 419-433.	2.3	28
10	Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 2980-2992.	1.1	25
11	Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 56.	3.5	25
12	Deconvolution of transcriptomes and miRNomes by independent component analysis provides insights into biological processes and clinical outcomes of melanoma patients. <i>BMC Medical Genomics</i> , 2019, 12, 132.	0.7	22
13	The TAT-RasGAP317-326 anti-cancer peptide can kill in a caspase-, apoptosis-, and necroptosis-independent manner. <i>Oncotarget</i> , 2016, 7, 64342-64359.	0.8	21
14	Integrative approaches for analysis of mRNA and microRNA high-throughput data. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 1154-1162.	1.9	20
15	miRNAs in ancient tissue specimens of the Tyrolean Iceman. <i>Molecular Biology and Evolution</i> , 2017, 34, msw291.	3.5	17
16	Cytokine-mediated modulation of the hepatic miRNome: miR-146b-5p is an IL-6-inducible miRNA with multiple targets. <i>Journal of Leukocyte Biology</i> , 2018, 104, 987-1002.	1.5	17
17	Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6744.	1.8	15
18	Cross-Linking Ligation and Sequencing of Hybrids (qCLASH) Reveals an Unpredicted miRNA Targetome in Melanoma Cells. <i>Cancers</i> , 2021, 13, 1096.	1.7	14

#	ARTICLE	IF	CITATIONS
19	The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by $\hat{\pm}$ -PD-L1 or $\hat{\pm}$ -IL6 antibodies. <i>Journal of Leukocyte Biology</i> , 2018, 104, 969-985.	1.5	12
20	Distinct Cargos of Small Extracellular Vesicles Derived from Hypoxic Cells and Their Effect on Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5071.	1.8	11
21	Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer. <i>International Journal of Cancer</i> , 2018, 142, 1010-1021.	2.3	11
22	Circulating microRNAs as Candidate Biomarkers for the Surveillance of Melanoma Patients. <i>EBioMedicine</i> , 2015, 2, 625-626.	2.7	3
23	Systematic Transcriptional Profiling of Responses to STAT1- and STAT3-Activating Cytokines in Different Cancer Types. <i>Journal of Molecular Biology</i> , 2020, 432, 5902-5919.	2.0	3